Literature DB >> 619054

Oral theophylline dosage for the management of chronic asthma.

R Wyatt, M Weinberger, L Hendeles.   

Abstract

Theophylline dosage requirements to maintain serum concentrations of 10 to 20 microgram/ml among asthmatic patients were examined in 156 children, ages 2 1/2 months to 16 years, and 33 otherwise health adults. Using 100% bioavailable preparations, low doses were used initially and increased, if tolerated, at three-day intervals. Final dosage was based on serum theophylline measurements which were subsequently repeated after six or more months of therapy. Dosage standardized by weight averaged 24.1 +/- 5.5 mg/kg/day (mean +/- SD) among the 77 children under age 9 years. Age-related variability of weight-adjusted doses were not observed for younger children, but average dose requirements decreased progressively beyound age 9 years to 13 mg/kg/day for patients beyoung 16 years of age. Although interpatient variability in dosage was confirmed at all ages, intrapatient variability in requirements over an average eight-month interval were small; dosage changes to maintain therapeutic serum concentration were primarily associated with growth. These data allow age-specific guidelines for dosage recommendations based on the likelihood of optimally effective and potentially toxic serum theophylline concentrations.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 619054     DOI: 10.1016/s0022-3476(78)80093-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  12 in total

1.  Advocating for patients through clinical research.

Authors:  Leslie Hendeles
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

Review 2.  Clinical pharmacokinetics of theophylline.

Authors:  R I Ogilvie
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

Review 3.  Monitoring serum theophylline levels.

Authors:  L Hendeles; M Weinberger; G Johnson
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

4.  Do saliva concentrations predict plasma unbound theophylline concentrations? A problem re-examined.

Authors:  C Knott; M Bateman; F Reynolds
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

Review 5.  Management of asthma in the child aged under 6 years.

Authors:  R S Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-13

6.  Serum level monitoring of a new slow release theophylline formulation in patients with chronic lung disease.

Authors:  G E Marlin; M A Butcher; J A Klumpp; P J Thompson
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

7.  A pharmacokinetic model-independent approach for estimating dose required to give desired steady-state trough concentrations of drug in plasma.

Authors:  J T Slattery
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

8.  Slow-release theophylline preparations.

Authors:  M Weinberger
Journal:  Arch Dis Child       Date:  1979-07       Impact factor: 3.791

Review 9.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

10.  Aging, cigarette smoking and oral theophylline requirement.

Authors:  T Talseth; N P Boye; J Kongerud; J E Bredesen
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.